drugset / Trial / NCT02868996
An Open Label, Phase 1b, Ascending Dose Study of DM199
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare intravenous dosing with subcutaneous dosing.
Timeline
- Start
- 2016-09
- Primary completion
- 2017-03
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant human tissue kallikrein | Protein / enzyme biologic | — | Intravenous |